
CLAIMS

What is claimed is:

1. Use of Compound **1**,



(Compound **1**)

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or lessening the severity of pain in a subject, wherein the medicament is to be administered in an amount of about 10 mg to about 300 mg of Compound **1**, or a pharmaceutically acceptable salt thereof, per day, optionally in an amount of about 20 mg to 200 mg of Compound **1**, or a pharmaceutically acceptable salt thereof, per day.

2. The use of claim 1, wherein the medicament is to be administered in an amount of about 10 mg to about 300 mg of Compound **1**, or a pharmaceutically acceptable salt thereof, on a first day,

optionally in an amount of about 20 mg to about 200 mg of Compound **1**, or a pharmaceutically acceptable salt thereof, on a first day,

optionally in an amount of about 20 mg to about 30 mg of Compound **1**, or a pharmaceutically acceptable salt thereof, on a first day,

optionally in an amount of about 60 mg to about 90 mg of Compound **1**, or a pharmaceutically acceptable salt thereof, on a first day,

optionally in an amount of about 100 mg to about 150 mg of Compound **1**, or a pharmaceutically acceptable salt thereof, on a first day,

optionally in an amount of about 5 mg to about 200 mg of Compound **1**, or a pharmaceutically acceptable salt thereof, per day after the first day.

3. The use of claim 1 or 2, wherein is to be administered in two doses per day, or is to be administered in a first dose and a subsequent dose on the first day, wherein the first dose is larger than the subsequent dose, optionally wherein the subsequent dose is to be administered 12 hours after the first dose.

4. The use of claim 3, wherein the first dose is between about 20 mg and about 100 mg of Compound **1**, or a pharmaceutically acceptable salt thereof,

optionally wherein the first dose is about 20 mg of Compound **1**, or a pharmaceutically acceptable salt thereof, or

optionally wherein the first dose is about 60 mg of Compound **1**, or a pharmaceutically acceptable salt thereof,, or

optionally wherein the first dose is about 100 mg of Compound **1**, or a pharmaceutically acceptable salt thereof,.

5. The use of claim 3 or 4, wherein the subsequent dose is between about 10 mg and about 100 mg of Compound **1**, or a pharmaceutically acceptable salt thereof, or

wherein the subsequent dose is between about 10 mg and about 50 mg of Compound **1**, or a pharmaceutically acceptable salt thereof, or

wherein the subsequent dose is about 10 mg of Compound **1**, or a pharmaceutically acceptable salt thereof, or

wherein the subsequent dose is about 30 mg of Compound **1**, or a pharmaceutically acceptable salt thereof, or

wherein the subsequent dose is about 50 mg of Compound **1**, or a pharmaceutically acceptable salt thereof,.

6. The use of any one of claims 2 to 5, wherein the medicament is to be administered in two doses per day after the first day, or

in two doses of about 10 mg to 50 mg of Compound **1**, or a pharmaceutically acceptable salt thereof, per day after the first day, or

in two doses of about 10 mg of Compound **1**, or a pharmaceutically acceptable salt thereof, per day after the first day, or

in two doses of about 30 mg of Compound **1**, or a pharmaceutically acceptable salt thereof, per day after the first day, or

in two doses of about 50 mg of Compound **1**, or a pharmaceutically acceptable salt thereof, per day after the first day.

7. The use of claim 6, wherein the medicament is to be administered with a 12 hour period between administration of each of the two doses.

8. The use of claim 1, wherein the medicament is to be administered in one dose per day.

9. The use of any one of claims 1 to 8, wherein the medicament is to be administered for at least 1 week, or for at least 6 weeks, or for at least two days.

10. The use of any one of claims 1 to 9, wherein the medicament is to be administered orally or intravenously.

11. The use of any one of claims 1 to 10, wherein the medicament is for treating or lessening the severity of chronic pain, gut pain, neuropathic pain optionally post-herpetic neuralgia, small-fiber neuropathy, idiopathic small-fiber neuropathy, diabetic neuropathy, or diabetic peripheral neuropathy; musculoskeletal pain optionally osteoarthritis pain, acute pain optionally acute post-operative pain, inflammatory pain, cancer pain, idiopathic pain, postsurgical pain optionally bunionectomy pain, abdominoplasty pain, or herniorrhaphy pain, or visceral pain in the subject, optionally wherein the pain is associated with multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough, or cardiac arrhythmia.

12. The use of any one of claims 1 to 11, wherein the medicament is to be administered to a subject that experienced a baseline pain score of at least 4 on an 11-point Numeric Pain Rating Scale prior to administration of the medicament.

13. The use of any one of claims 1 to 11, wherein the medicament is to be administered to a subject that experienced a baseline pain level of moderate or severe on a Verbal Categorical Rating Scale prior to administration of the medicament.

14. The use of any one of claims 1 to 13, wherein the medicament comprises Compound **1** in non-salt form.

15. The use of any one of claims 1 to 14, wherein the medicament is to be administered concurrently with, prior to, or subsequent to treatment with one or more additional therapeutic agents.

16. A solid dispersion comprising:
(2*R*,3*S*,4*S*,5*R*)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide (Compound **1**) or a pharmaceutically acceptable salt thereof; and
at least one polymer.

17. The solid dispersion of claim 16, wherein Compound **1**, or a pharmaceutically acceptable salt thereof, and the polymer are co-spray-dried with a solvent, optionally wherein the polymer is selected from: hydroxypropyl methylcellulose acetate succinate (HPMCAS), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft co-polymer, and any combination thereof, optionally wherein the polymer is HPMCAS.

18. The solid dispersion of claim 16 or 17, wherein the solid dispersion comprises:

about 20 wt % to about 50 wt % of Compound **1**, or a pharmaceutically acceptable salt thereof; and about 50 wt % to about 80 wt % of the polymer,

optionally about 25 wt % of Compound 1, or a pharmaceutically acceptable salt thereof; and

optionally about 75 wt % of the polymer.

19. The solid dispersion of any one of claims 16 to 18, wherein Compound **1** is substantially amorphous.

20. A pharmaceutical composition comprising the solid dispersion of any one of claims 16 to 19, optionally wherein the pharmaceutical composition is a tablet.

21. The pharmaceutical composition of claim 20, wherein the pharmaceutical composition further comprises one or more excipients selected from: at least one filler optionally 72.5 wt %, at least one disintegrant optionally 4.5 wt %, at least one lubricant optionally 3 wt %, and any combination thereof.

22. The pharmaceutical composition of claim 20, wherein the pharmaceutical composition further comprises at least one polymer, at least one filler, at least one lubricant, and at least one disintegrant.

23. The pharmaceutical composition of claim 21, wherein the filler is selected from: microcrystalline cellulose, lactose monohydrate, mannitol, and any combination thereof;

optionally wherein the disintegrant is selected from: croscarmellose sodium, crospovidone, and any combination thereof;

optionally wherein the lubricant is selected from: sodium stearyl fumarate, magnesium stearate, and any combination thereof;

optionally wherein the filler comprises microcrystalline cellulose and lactose monohydrate and the disintegrant comprises croscarmellose sodium, and wherein the lubricant comprises sodium stearyl fumarate.

24. The pharmaceutical composition of any one of claims 20 to 23, wherein the pharmaceutical composition comprises about 1 to about 50 mg optionally about 10 mg, of Compound **1**, or a pharmaceutically acceptable salt thereof.

25. The use of any one of claims 1 to 15, wherein the medicament comprises the pharmaceutical composition of any one of claims 20 to 24.

26. The use of claim 1, wherein the medicament is to be administered in an amount of about 50 mg to about 150 mg of Compound **1**, or a pharmaceutically acceptable salt thereof, on a first day.

27. The use of claim 1, wherein the medicament is to be administered in an amount of about 20 mg to about 100 mg of Compound **1**, or a pharmaceutically acceptable salt thereof, on a first day.